Victoza is a liraglutide injection used to treat type 2 diabetes and aid in weight loss for individuals with obesity or overweight conditions. Liraglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that works by stimulating insulin secretion, decreasing glucagon release, and slowing gastric emptying, helping to lower blood sugar levels after meals. Additionally, it has been shown to reduce appetite and support weight loss.
Victoza is administered via a subcutaneous injection, typically once a day, and can be used alone or in combination with other diabetes medications. Its dual benefits of improving blood glucose control and promoting weight loss make it an essential medication for managing type 2 diabetes and obesity.
✅ Type 2 Diabetes Management — helps lower blood sugar by increasing insulin production in response to meals
✅ Weight Loss and Obesity Management — aids in weight reduction, especially for individuals with type 2 diabetes and BMI ≥ 30 kg/m²
✅ Prevention of Cardiovascular Events — demonstrated to reduce the risk of heart attacks, strokes, and cardiovascular death in patients with diabetes
Improves blood sugar control: Helps regulate post-meal blood sugar spikes and maintains glucose levels.
Aids in weight loss: Reduces appetite, which leads to lower calorie intake and enhanced weight management.
Cardiovascular benefits: Reduces the risk of major cardiovascular events like heart attack and stroke in people with type 2 diabetes.
Convenient administration: Once-daily subcutaneous injection, making it easy to integrate into daily routines.
Victoza contains liraglutide, a GLP-1 receptor agonist, which mimics the effects of the natural GLP-1 hormone in the body. GLP-1 enhances insulin secretion in response to meals, helps reduce glucagon release (which reduces glucose production by the liver), and delays gastric emptying. These actions help lower blood sugar and reduce hunger, promoting weight loss in patients who are obese or overweight.
Victoza is a liraglutide injection used to treat type 2 diabetes and aid in weight loss for individuals with obesity or overweight conditions. Liraglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that works by stimulating insulin secretion, decreasing glucagon release, and slowing gastric emptying, helping to lower blood sugar levels after meals. Additionally, it has been shown to reduce appetite and support weight loss.
Victoza is administered via a subcutaneous injection, typically once a day, and can be used alone or in combination with other diabetes medications. Its dual benefits of improving blood glucose control and promoting weight loss make it an essential medication for managing type 2 diabetes and obesity.
✅ Type 2 Diabetes Management — helps lower blood sugar by increasing insulin production in response to meals
✅ Weight Loss and Obesity Management — aids in weight reduction, especially for individuals with type 2 diabetes and BMI ≥ 30 kg/m²
✅ Prevention of Cardiovascular Events — demonstrated to reduce the risk of heart attacks, strokes, and cardiovascular death in patients with diabetes
Improves blood sugar control: Helps regulate post-meal blood sugar spikes and maintains glucose levels.
Aids in weight loss: Reduces appetite, which leads to lower calorie intake and enhanced weight management.
Cardiovascular benefits: Reduces the risk of major cardiovascular events like heart attack and stroke in people with type 2 diabetes.
Convenient administration: Once-daily subcutaneous injection, making it easy to integrate into daily routines.
Victoza contains liraglutide, a GLP-1 receptor agonist, which mimics the effects of the natural GLP-1 hormone in the body. GLP-1 enhances insulin secretion in response to meals, helps reduce glucagon release (which reduces glucose production by the liver), and delays gastric emptying. These actions help lower blood sugar and reduce hunger, promoting weight loss in patients who are obese or overweight.